Showing results (161-170 of 279) with videos related to

Sort By:
Pageof 28
Hematological Oncology|April 24, 2019
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasmsTariq I Mughal, Naveen Pemmaraju, Jerald P Radich, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2021
Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitorsLu Cui, Ignacio Moraga, Tristan Lerbs, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2020
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosisKarin Hartmann, Jason Gotlib, Cem Akin, et al.
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia VeraAlexander Coltoff, Ruben Mesa, Jason Gotlib, et al.
The World Allergy Organization Journal|March 23, 2026
Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosisThanai Pongdee, Mariana Castells, Cem Akin, et al.
Leukemia Research|February 22, 2018
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasmsTariq I Mughal, Jason Gotlib, Ruben Mesa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2010
Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangementsScott D Boyd, Bruno A Gaëta, Katherine J Jackson, et al.
Blood|December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Pageof 28